Nivolumab and bevacizumab attenuate cisplatin-induced hepatic inflammation and apoptosis in rats [0.03%]
尼伏单抗和贝伐单抗减轻顺铂致大鼠肝炎及凋亡
Ogur Karhan,Sibel Turedi
Ogur Karhan
Background and aim: Hepatotoxicity represents a significant adverse effect associated with cancer treatment. The present study was designed to evaluate the possible hepatoprotective effects of bevacizumab and nivolumab wh...
Hepatic granulomas heralding eosinophilic granulomatosis with polyangiitis overlapping with Sjögren's syndrome [0.03%]
肝脏肉芽肿性损害提示重叠有干燥综合征的嗜酸细胞性肉芽肿伴多血管炎
Tayssir Ben Achour,Fatma Saïd,Abir Chérif et al.
Tayssir Ben Achour et al.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) encompass a group of rare autoimmune diseases characterized by granuloma formation and/or inflammation of small vessels. The clinical spectrum of AAV varies widely. ...
Case Reports
Hepatology forum. 2025 Sep 24;7(1):77-80. DOI:10.14744/hf.2025.45561 2025
Hepatic steatosis is associated with HBsAg seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression [0.03%]
肝脂肪变与慢性乙肝患者的HBsAg自发清除有关但也会导致疾病进展
Emin Bodakci,Saba Kiremitci,Zeynep Melekoglu Ellik et al.
Emin Bodakci et al.
Background and aim: The present study aimed to determine the effect of hepatic steatosis, as detected by liver biopsy, on Hepatitis B surface antigen (HbsAg) seroclearance and disease progression in patients infected with...
Sarcopenia as a novel biomarker for predicting TIPS outcomes in cirrhotic patients with refractory ascites: Mechanisms linking muscle loss, metabolic dysregulation, and portal hemodynamics [0.03%]
肌少症作为预测难治性腹水肝硬化患者经颈静脉肝内门体分流术预后的新型生物标志物：肌肉丢失、代谢失调和门脉血流动力学之间的关联机制
Miao Li,Panpan Jin,Yi Shan et al.
Miao Li et al.
Background and aim: Transjugular intrahepatic portosystemic shunt (TIPS) is pivotal for refractory ascites in cirrhosis, yet many patients experience poor outcomes. Sarcopenia, a common muscle-wasting syndrome in cirrhosi...
Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy [0.03%]
评估替诺福韦阿拉芬酰胺治疗HBV感染的化疗/免疫抑制治疗患者的有效性和耐受性
Feyza Dilber,Serdar Durak,Yasemin Unsal et al.
Feyza Dilber et al.
Background and aim: This study aimed to determine the efficacy and safety of tenofovir alafenamide fumarate (TAF) prophylaxis in hepatitis B virus (HBV)-infected or HBV-experienced individuals with benign and malignant di...
Future burden of MASLD in the United States: A state-level forecasting study, 2022-2050 [0.03%]
美国慢加速性肝肾综合征未来负担：2022至2050年的州级预测研究
Thanathip Suenghataiphorn,Kanachai Boonpiraks,Vitchapong Prasitsumrit et al.
Thanathip Suenghataiphorn et al.
Background and aim: The rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) poses a significant public health challenge, yet the future burden at a subnational level is poorly quantified....
Can Cindoruk,Ali Emre Bardak,Eda Yildiz et al.
Can Cindoruk et al.
Endoscopic ultrasound (EUS) is being increasingly used for both diagnostic and therapeutic purposes in various settings in gastroenterology and hepatology. Similarly, it has also been adopted in liver transplantation (LT), and its utilizati...
When viral quiescence meets metabolic injury: Rethinking risk and treatment at the intersection of MASLD and chronic hepatitis B [0.03%]
病毒静止与代谢损伤相遇：重新思考慢性乙型肝炎和肝硬化交集处的风险和治疗
Dilara Turan Gokce,Ulus Salih Akarca
Dilara Turan Gokce
Role of insulin-like growth factor/receptor signaling in hepatocellular carcinoma [0.03%]
胰岛素样生长因子/受体信号转导在肝细胞癌中的作用
Sonia Bisht,Uma Sharma,Sangeetha Gupta
Sonia Bisht
Hepatocellular carcinoma (HCC) is one of the most common and deadly forms of liver cancer worldwide. Recent research suggests that the insulin-like growth factor (IGF) system, including insulin-like growth factor-1, insulin-like growth fact...
MASLD and viral hepatitis overlap: An emerging dual burden in chronic liver disease [0.03%]
MASLD与病毒性肝炎重叠：慢性肝病中出现的双重负担
Maham Ejaz,Kirsh Kumar,Daniyal Sohail et al.
Maham Ejaz et al.
The coexistence of metabolic dysfunction-associated steatotic liver disease (MASLD) and viral hepatitis has gained greater focus due to the global increase in chronic liver diseases. This convergence of conditions creates a unique clinical ...